| JCI |
Report |
Adjusted EPS (fiscal Q3 2026) |
BEAT |
pred ~$1.35 vs. cons $1.33 |
MEDIUM |
| JCI |
Report |
Organic sales growth (fiscal Q3 2026) |
BEAT |
pred ~6.4% vs. cons 6.0% |
MEDIUM |
| JCI |
Report |
Organic orders growth (fiscal Q3 2026) |
BEAT |
pred ~18% vs. cons 15% |
LOW |
| JCI |
Guide |
Adjusted EPS |
BETTER |
guide ~$4.95 vs. cons $4.90 (fiscal 2026) |
MEDIUM |
| JCI |
Guide |
Organic sales growth |
BETTER |
guide ~6.5% vs. cons 6.0% (fiscal 2026) |
MEDIUM |
| JCI |
Guide |
Implied adjusted EPS |
BETTER |
guide ~$1.52 vs. cons $1.49 (fiscal Q4 2026) |
MEDIUM |
| JCI |
Guide |
Adjusted free-cash-flow conversion |
UNCHANGED |
guide ~100% vs. cons 100% (fiscal 2026) |
HIGH |
| JCI |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.2% |
— |
MEDIUM |
| JCI |
Return |
5-day cumulative residual |
+3.4% (FOLLOW-THROUGH) |
The ~$4.95 fiscal-2026 guide combined with predicted Q3 EPS of ~$1.35 implies roughly $1.52 of Q4 EPS versus consensus near $1.49, supporting modest upward revisions; continued double-digit orders should also lift fiscal-2027 estimates, although the elevated valuation limits the magnitude. |
MEDIUM |